4basebio (4BB)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

745.00p
   
  • Change Today:
      10.00p
  • 52 Week High: 750.00
  • 52 Week Low: 400.00
  • Currency: UK Pounds
  • Shares Issued: 12.32m
  • Volume: 11,296
  • Market Cap: 91.77m

4basebio Overview

4basebio UK Societas ("4bb" or "the Company") is a specialist life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. Its main country of operation is the UK. It is the intention of the Company to become a market leader in the manufacture and supply of high purity, synthetic DNA for research, therapeutic and pharmacological use. The principal objective of 4bb is to validate and scale its DNA synthesis process with a view to manufacturing Good Manufacturing Practice ("GMP") grade DNA, suitable for use in gene therapies and DNA vaccines.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -1043.5% n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 271.5 n/a
Pr/Book 7.8  
Latest F'cast
Revenue -26.8% n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

4basebio Fundamentals

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-19 0.20 (0.53) (5.00)p n/a n/a n/a n/a 0.0%
31-Dec-20 0.46 (0.72) (8.00)p n/a n/a n/a n/a 0.0%
31-Dec-21 0.34 (3.64) (26.00)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

4basebio Company Announcements

4basebio Plc - Half-year Report 30-Sep-2022 07:00 PR Newswire
Second Price Monitoring Extn 27-Sep-2022 09:05 RNS
Price Monitoring Extension 27-Sep-2022 09:00 RNS

Latest 4basebio Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

4basebio Market Data

Currency UK Pounds
Share Price 745.00p
Change Today 10.00p
% Change 1.36 %
52 Week High 750.00
52 Week Low 400.00
Volume 11,296
Shares Issued 12.32m
Market Cap 91.77m

4basebio Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
62.98% below the market average62.98% below the market average62.98% below the market average62.98% below the market average62.98% below the market average
19.3% below the sector average19.3% below the sector average19.3% below the sector average19.3% below the sector average19.3% below the sector average
Price Trend
77.66% above the market average77.66% above the market average77.66% above the market average77.66% above the market average77.66% above the market average
80.65% above the sector average80.65% above the sector average80.65% above the sector average80.65% above the sector average80.65% above the sector average
Income Not Available
Growth
6.25% below the market average6.25% below the market average6.25% below the market average6.25% below the market average6.25% below the market average
15.00% above the sector average15.00% above the sector average15.00% above the sector average15.00% above the sector average15.00% above the sector average

4basebio Dividends

No dividends found

Trades for 02-Feb-2023

Time Volume / Share Price
16:35 318 @ 745.00p
16:35 318 @ 745.00p
16:07 275 @ 749.00p
15:43 800 @ 730.00p
14:00 1,000 @ 737.00p

4basebio Key Personnel

CEO Heikki Lanckriet
CFO David John Roth

Top of Page